Researchers estimated that 40% of children with B-cell acute lymphoblastic leukemia who received the chimeric antigen receptor T-cell therapy Kymriah, or tisagenlecleucel, would survive after five years, compared with only 10.8% of those who were given clofarabine. The findings in JAMA Pediatrics also showed that tisagenlecleucel had a nearly $46,000 difference per quality-adjusted life year gained, compared with clofarabine, indicating its cost-effectiveness in treating pediatric ALL.
Cost-effectiveness of pediatric leukemia CAR T-cell therapy studied
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.